Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255814 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy in Treating Patients With Liver Metastases
A Phase 1 study of Metastatic Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 3
- Study locations
NCT00255814 is a Phase 1 study of Metastatic Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 26 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00255814, a Phase 1 study of Metastatic Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy in treating patients with liver metastases.
Conditions Studied
Interventions
- RADIATION radiation therapy
Study Locations (3)
New York
- James P. Wilmot Cancer Center at University of Rochester Medical Center - Rochester
Ontario
- Princess Margaret Hospital - Toronto
Quebec
- McGill Cancer Centre at McGill University - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255814
The ClinicalTrials.gov registry entry for NCT00255814 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which radiation therapy is the first listed.
NCT00255814 reports 3 study locations spanning 3 distinct geographic areas - top geographies include New York, Ontario, Quebec.
Frequently Asked Questions
What is clinical trial NCT00255814 about?
NCT00255814 is a clinical study titled "Radiation Therapy in Treating Patients With Liver Metastases". RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy in treating patients with liver metasta...
What is the current status of trial NCT00255814?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2005-11. Estimated completion is 2013-11.
What conditions does trial NCT00255814 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT00255814?
The interventions under investigation include: radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00255814?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00255814 being conducted?
This trial has 3 study locations across New York, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.